Localized prostate cancer

[1]  R. Parker,et al.  Adjuvant radiation therapy after radical prostatectomy for carcinoma of the prostate. , 1997, American journal of clinical oncology.

[2]  P T Scardino,et al.  Conservative management of prostate cancer. , 1994, The New England journal of medicine.

[3]  M. Blute,et al.  Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. , 1995, The Journal of urology.

[4]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[5]  P. Kantoff,et al.  NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. , 1996, Oncology.

[6]  Michael J. Zelefsky,et al.  Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .

[7]  M W Kattan,et al.  Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. , 1996, The Journal of urology.

[8]  M. Kattan,et al.  Factors predicting recovery of erections after radical prostatectomy. , 2000, The Journal of urology.

[9]  T. Stamey,et al.  Morphometric and clinical studies on 68 consecutive radical prostatectomies. , 1988, The Journal of urology.

[10]  M. Zelefsky,et al.  Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. , 1997, Urology.

[11]  T. Stamey,et al.  Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.

[12]  E. Barrett-Connor,et al.  A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. , 1990, Cancer research.

[13]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  R A Stephenson,et al.  Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.

[15]  B. Dalkin,et al.  Endoscopic evaluation and treatment of anastomotic strictures after radical retropubic prostatectomy. , 1996, The Journal of urology.

[16]  G. Schwartz,et al.  Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.

[17]  G. Perry,et al.  Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. , 2000, International journal of radiation oncology, biology, physics.

[18]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[19]  R. Hautmann,et al.  Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. , 1994, Urology.

[20]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[21]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[22]  R. Badalament,et al.  Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens , 1995, Cancer.

[23]  A. Zlotta,et al.  Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. , 1998, British journal of urology.

[24]  Thomas M. Wheeler,et al.  A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer , 1998 .

[25]  M. Benson,et al.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. , 1994, Urology.

[26]  P. Scardino,et al.  Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? , 1995, Urology.

[27]  Modena E. H. Wilson,et al.  Screening for Prostate Cancer: Commentary on the Recommendations of the Canadian Task Force on the Periodic Health Examination , 1994 .

[28]  T. Stamey,et al.  Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. , 1998, The Journal of urology.

[29]  T. Wheeler,et al.  Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer. , 1994, The Journal of urology.

[30]  N. Vogelzang.  Comprehensive Textbook of Genitourinary Oncology , 1996 .

[31]  M. Kattan,et al.  Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. , 1998, Human pathology.

[32]  B. Turnbull,et al.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. , 1998, British journal of urology.

[33]  D. Grignon,et al.  Allelic loss in locally metastatic, multisampled prostate cancer. , 1994, Cancer research.

[34]  W. Ellis,et al.  Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  P. Scardino,et al.  The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. , 1991, The Journal of urology.

[36]  M. Cowen,et al.  A Markov model of the natural history of prostate cancer. , 1994, Journal of clinical epidemiology.

[37]  H. Peterson,et al.  Vasectomy and prostate cancer. Chance, bias, or a causal relationship? , 1993, JAMA.

[38]  M. Akahane,et al.  Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. , 2001, The Journal of urology.

[39]  P. Kantoff,et al.  The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. , 1998, Biochimica et biophysica acta.

[40]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[41]  R. Kane,et al.  American cancer society–national prostate cancer detection project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen , 1993, Cancer.

[42]  M W Kattan,et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Scardino,et al.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. , 1999, Human gene therapy.

[44]  V. Steele,et al.  Chemopreventive drug development: perspectives and progress. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  B. Hølund.  Latent prostatic cancer in a consecutive autopsy series. , 1980, Scandinavian journal of urology and nephrology.

[46]  J. Fowler,et al.  Original Articles: Prostate Cancer: Variable Histology of Anastomotic Biopsies With Detectable Prostate Specific Antigen After Radical Prostatectomy , 1995 .

[47]  T. Stamey,et al.  Positive surgical margins at radical prostatectomy: importance of the apical dissection. , 1990, The Journal of urology.

[48]  Brian J. Miles,et al.  A Decision Analysis for Treatment of Clinically Localized Prostate Cancer , 1997 .

[49]  T. Stamey,et al.  Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. , 1993, The Journal of urology.

[50]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 1999, Journal of the National Cancer Institute.

[51]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[52]  M. Kattan,et al.  Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? , 1997, The Journal of urology.

[53]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[54]  P. Scardino,et al.  Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.

[55]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[57]  J. Montie,et al.  Salvage surgery for radiation failure in prostate cancer , 1993, Cancer.

[58]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[59]  A. Hanlon,et al.  Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. , 1994, International journal of radiation oncology, biology, physics.

[60]  C. Ling,et al.  Analysis of biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer using dose-distribution variables and tumor control probability models. , 2000, International journal of radiation oncology, biology, physics.

[61]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[62]  Farhat Abbas,et al.  The natural history of clinical prostate carcinoma , 1997, Cancer.

[63]  P. Carroll,et al.  Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. , 2000, The Journal of urology.

[64]  P C Prorok,et al.  Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. , 1994, The Journal of urology.

[65]  F. Vicini,et al.  Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. , 1999, Urology.

[66]  S. Schild,et al.  The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. , 1996, The Journal of urology.

[67]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[68]  J. Fowler,et al.  Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. , 1995, The Journal of urology.

[69]  A. Hanlon,et al.  Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. , 1996, The Journal of urology.

[70]  M. Sporn,et al.  Can dietary beta-carotene materially reduce human cancer rates? , 1981, Nature.

[71]  M. Zelefsky,et al.  Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues. , 1999, The American journal of surgical pathology.

[72]  B. Guillonneau,et al.  Laparoscopic radical prostatectomy: Initial experience and preliminary assessment after 65 operations , 1999, The Prostate.

[73]  G. Murphy,et al.  National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. , 1994, The Journal of urology.

[74]  M. Kattan,et al.  Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. , 2002, The Journal of urology.

[75]  K. Wallner,et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[76]  P. Walsh,et al.  Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. , 1991, The Journal of urology.

[77]  M. Kattan,et al.  Radical retropubic prostatectomy: limited benefit of autologous blood donation. , 1995, The Journal of urology.

[78]  G. Duchesne,et al.  Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[79]  J M Collins,et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. , 1998, International journal of radiation oncology, biology, physics.

[80]  T. Wilt,et al.  The prostate cancer intervention versus observation trial (PIVOT). A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer , 1995, Oncology.

[81]  M. Srougi,et al.  Urinary continence and pathological outcome after bladder neck preservation during radical retropubic prostatectomy: a randomized prospective trial. , 2001, The Journal of urology.

[82]  M. Kattan,et al.  Risk factors for complications and morbidity after radical retropubic prostatectomy. , 1997, The Journal of urology.

[83]  G A Colditz,et al.  Intake of carotenoids and retinol in relation to risk of prostate cancer. , 1995, Journal of the National Cancer Institute.

[84]  A. K. Levinson,et al.  Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  W. Whitmore,et al.  Expectant management of clinically localized prostatic cancer. , 1994, The Journal of urology.

[86]  F. Collins,et al.  Evidence for a prostate cancer susceptibility locus on the X chromosome. , 1998, Nature Genetics.

[87]  T. Wheeler.  Anatomic considerations in carcinoma of the prostate. , 1989, The Urologic clinics of North America.

[88]  P. Albertsen,et al.  Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy--a population-based study. , 1999, Urology.

[89]  M. Bagshaw,et al.  Radiation therapy for localized disease , 1993 .

[90]  M. Anscher,et al.  Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. , 1995, International journal of radiation oncology, biology, physics.

[91]  W. Höltl,et al.  Bladder neck strictures after radical retropubic prostatectomy: still an unsolved problem. , 1998, British journal of urology.

[92]  M. Conaway,et al.  Serum androgens: associations with prostate cancer risk and hair patterning. , 1997, Journal of andrology.

[93]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[94]  P. Scardino,et al.  The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer. , 1991, The Journal of urology.

[95]  M. Mushinski,et al.  Probabilities of eventually developing or dying of cancer—united states, 1985 , 1985, CA: a cancer journal for clinicians.

[96]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[97]  L. Baert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995, The Journal of urology.

[98]  M. Toublanc,et al.  Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions. , 1998, The Journal of urology.

[99]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[100]  T. Stamey,et al.  Invasion of Denonvilliers' fascia in radical prostatectomy specimens. , 1993, The Journal of urology.

[101]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[102]  P. Scardino,et al.  The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. , 1989, The Journal of urology.

[103]  D. Grignon,et al.  Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. , 1998, Urology.

[104]  Zelefsky Mj.  The emerging role of neoadjuvant hormonal therapy in the management of localized prostatic cancer--reply. , 1997 .

[105]  T. Stamey,et al.  Making the most out of six systematic sextant biopsies. , 1995, Urology.

[106]  S. Schwartz,et al.  Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. , 1999, The Journal of urology.

[107]  J. Brooks,et al.  Molecular biology of prostate cancer progression. , 1995, Cancer surveys.

[108]  D. Beyer,et al.  Biochemical disease-free survival following 125I prostate implantation. , 1997, International journal of radiation oncology, biology, physics.

[109]  R. B. Smith,et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. , 1994, The Journal of urology.

[110]  M. Kattan,et al.  Risk factors for urinary incontinence after radical prostatectomy. , 1996, The Journal of urology.

[111]  J. Holland,et al.  Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. , 1996, The Journal of urology.

[112]  P. Scardino,et al.  Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. , 1993, British journal of urology.

[113]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[114]  P. Scardino,et al.  Rationale for and results of nerve grafting during radical prostatectomy. , 2001, Urology.

[115]  P. Walsh,et al.  Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade. , 1981, The Journal of urology.

[116]  W. Kirkels,et al.  The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. , 1999, The Journal of urology.

[117]  R. Stock,et al.  The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. , 1997, Seminars in surgical oncology.

[118]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[119]  T. Stamey,et al.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.

[120]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[121]  M. Kattan,et al.  The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer. , 1996, British journal of urology.

[122]  P. Scardino,et al.  Use of Systematic Biopsy Results to Predict Pathologic Stage in Patients with Clinically Localized Prostate Cancer: A Preliminary Report , 1998, International journal of urology : official journal of the Japanese Urological Association.

[123]  C. Brendler,et al.  Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. , 1998, The Journal of urology.

[124]  W. Whitmore,et al.  The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer , 1981, Cancer.

[125]  L. Bernstein,et al.  Serum testosterone levels in healthy young black and white men. , 1986, Journal of the National Cancer Institute.

[126]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[127]  R. Parker,et al.  Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. , 1998, The cancer journal from Scientific American.

[128]  H. Scher,et al.  Clinical states in prostate cancer: toward a dynamic model of disease progression. , 2000, Urology.

[129]  J. Earle,et al.  Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. , 2000, American journal of clinical oncology.

[130]  D. Bostwick,et al.  Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. , 1996, Urology.

[131]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[132]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[133]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  H. Reich,et al.  Transperitoneal endosurgical lymphadenectomy in patients with localized prostate cancer. , 1991, The Journal of urology.

[135]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[136]  A. Zietman,et al.  Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. , 1994, The Journal of urology.

[137]  P. Rubin,et al.  Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. , 1995, International journal of radiation oncology, biology, physics.

[138]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[139]  C. Öbek,et al.  Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. , 1999, Urology.

[140]  S. Cha,et al.  Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. , 1997, Urology.

[141]  J. Chapelon,et al.  Treatment of localised prostate cancer with transrectal high intensity focused ultrasound. , 1999, European journal of ultrasound : official journal of the European Federation of Societies for Ultrasound in Medicine and Biology.

[142]  G. Murphy,et al.  American Cancer Society guideline for the early detection of prostate cancer: Update 1997 , 1997, CA: a cancer journal for clinicians.

[143]  W. H. Williams,et al.  Simultaneous radiotherapy for prostate cancer: 125I prostate implant followed by external-beam radiation. , 1998, The cancer journal from Scientific American.

[144]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[145]  T. French,et al.  Adult dietary intake and prostate cancer risk in Utah: a case-control study with special emphasis on aggressive tumors , 1991, Cancer Causes & Control.

[146]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[147]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[148]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[149]  A. Partin,et al.  Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. , 1994, The Journal of urology.

[150]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[151]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[152]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[153]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[154]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[155]  R. Mark,et al.  Postoperative radiation therapy after radical prostatectomy for prostate carcinoma , 1992, Cancer.

[156]  J. Goellner,et al.  Prostate shape, external striated urethral sphincter and radical prostatectomy: the apical dissection. , 1987, The Journal of urology.

[157]  J. Hugosson,et al.  Long-term survival and mortality in prostate cancer treated with noncurative intent. , 1995, The Journal of urology.

[158]  G. Murphy,et al.  The national cancer data base report on prostate cancer , 1995, Cancer.

[159]  S. Woolf.  Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.

[160]  J. Stanford,et al.  Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. , 1999, Journal of the National Cancer Institute.

[161]  H. Zincke,et al.  Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer. , 1995, Oncology.

[162]  Jerome P. Richie,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[163]  P. Scardino,et al.  The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer , 1994, Cancer.

[164]  W. Catalona,et al.  Early complications of contemporary anatomical radical retropubic prostatectomy. , 1994, The Journal of urology.

[165]  P. Scardino,et al.  Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. , 1995, The Journal of urology.

[166]  D. Wood,et al.  Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. , 2002, The Journal of urology.

[167]  A. Renshaw,et al.  Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Spitz,et al.  Epidemiologic determinants of clinically relevant prostate cancer , 2000, International journal of cancer.

[169]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.

[170]  Gleason Df.  Histologic grade, clinical stage, and patient age in prostate cancer. , 1988 .

[171]  D. Bostwick,et al.  Pathologic classification of prostate carcinoma , 1998, Cancer.

[172]  W. Catalona,et al.  Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.

[173]  P. Scardino,et al.  The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in patients with localized prostate cancer. , 1989, The Journal of urology.

[174]  B. Mittal,et al.  The role of adjuvant irradiation following primary prostatectomy, based on histopathologic extent of tumor. , 1989, International journal of radiation oncology, biology, physics.

[175]  P. Scardino,et al.  Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. , 1994, The Journal of urology.

[176]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[177]  A. V. von Eschenbach,et al.  Prognostic factors for clinically localized prostate carcinoma , 1997, Cancer.

[178]  P. Scardino,et al.  Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. , 1996, The Urologic clinics of North America.

[179]  J. Horm,et al.  Current status of prostate cancer in North American black males. , 1990, Journal of the National Medical Association.

[180]  A. Whittemore,et al.  Dietary fat, calories, and prostate cancer risk. , 1999, Journal of the National Cancer Institute.

[181]  F. Lee,et al.  Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.

[182]  P. Scardino,et al.  Early detection of prostate cancer. , 1989, The Urologic clinics of North America.

[183]  M. Barry,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.

[184]  J. Bachaud,et al.  Compte rendu du 38e congrès de l'American Society for Therapeutic Radiology and Oncology (ASTRO), Los Angeles, 27–31 octobre 1996 , 1997 .

[185]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[186]  J. Forman,et al.  Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. , 1998, Urology.

[187]  A. Zietman,et al.  Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[188]  W. Catalona,et al.  Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. , 1999, The Journal of urology.

[189]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[190]  M. Hafermann,et al.  Adjuvant radiotherapy following radical prostatectomy: results and complications. , 1986, The Journal of urology.

[191]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[192]  J. Chin,et al.  CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group. , 1999, Urology.

[193]  P C Prorok,et al.  Prostate Cancer Screening: What We Know and What We Need To Know , 1993, Annals of Internal Medicine.

[194]  P. Scardino,et al.  A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. , 1991, The Journal of urology.

[195]  P. Scardino,et al.  The Mechanisms and Prognostic Significance of Seminal Vesicle Involvement by Prostate Cancer , 1993, The American journal of surgical pathology.

[196]  D. Bostwick,et al.  Prostatic Intra‐Epithelial Neoplasia and Early Invasion in Prostate Cancer , 1987, Cancer.

[197]  H. Levin,et al.  Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer , 1989, Cancer.

[198]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[199]  J. Adolfsson,et al.  Deferred treatment of low grade stage T3 prostate cancer without distant metastases. , 1993, The Journal of urology.

[200]  J. Moul,et al.  Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. , 1990, The Journal of urology.

[201]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[202]  R. Kane,et al.  Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .

[203]  Gleason Df.  Classification of prostatic carcinomas. , 1966 .

[204]  M. Ohori,et al.  Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. , 1994, Seminars in Oncology.

[205]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[206]  D. Bostwick.  Prospective origins of prostate carcinoma: Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia , 1996, Cancer.

[207]  D. Bostwick,et al.  Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma. , 1998, Analytical and quantitative cytology and histology.

[208]  W. Catalona,et al.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. , 1994, The Journal of urology.

[209]  F. Debruyne,et al.  Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma , 1997 .

[210]  J. Richie,et al.  Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[211]  A. Polednak,et al.  Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in connecticut , 1992 .

[212]  B. Guillonneau,et al.  Laparoscopic radical prostatectomy: the Montsouris experience. , 2000, The Journal of urology.

[213]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[214]  M. Kattan,et al.  Assessment of the biologic markers p53, ki‐67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery , 1998 .

[215]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[216]  Peter Tugwell,et al.  Randomized Trial of a Portable, Self-administered Decision Aid for Postmenopausal Women Considering Long-term Preventive Hormone Therapy , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[217]  M. Soloway,et al.  Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[218]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[219]  T. Stamey,et al.  An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. , 2000, The Journal of urology.

[220]  P. Humphrey,et al.  The early detection of prostate carcinoma with prostate specific antigen , 1997, Cancer.

[221]  M. Soloway,et al.  Small cell carcinoma of the bladder and prostate. , 1995, Urology.

[222]  T. Stamey,et al.  Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.

[223]  Schwartz Gg,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990 .

[224]  H. C. Graves,et al.  Nonprostatic sources of prostate-specific antigen: a steroid hormone-dependent phenomenon? , 1995, Clinical chemistry.

[225]  W. Catalona,et al.  Interexaminer variability of digital rectal examination in detecting prostate cancer. , 1995, Urology.

[226]  C C Ling,et al.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[227]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[228]  M. Blute,et al.  Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. , 1999, The Journal of urology.

[229]  B. Rimer,et al.  Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. , 1995, Urology.

[230]  P. Scardino,et al.  Impalpable prostate cancer: clinicopathological features. , 1996, British journal of urology.

[231]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[232]  G. Murphy,et al.  The national cancer data base report on prostate cancer , 1995 .

[233]  H. Hricak,et al.  Imaging prostate cancer. , 1999, The Journal of urology.

[234]  E. Rimm,et al.  Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[235]  Michael W Kattan,et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.

[236]  Haakon Ragde,et al.  Modern prostate brachytherapy , 2000 .

[237]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[238]  P. Scardino,et al.  Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? , 1994, The Journal of urology.

[239]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[240]  M. J. Hoeksema,et al.  Cancer mortality rates fall: a turning point for the nation. , 1996, Journal of the National Cancer Institute.

[241]  E. B. Butler,et al.  Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[242]  Samuel Hellman,et al.  Important advances in oncology , 1991 .

[243]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[244]  L. Baert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. , 1995 .

[245]  P. Scardino,et al.  Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. , 1992, The Journal of urology.

[246]  W. Sakr,et al.  Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis , 1993, Genes, chromosomes & cancer.

[247]  T. Beaty,et al.  Mendelian inheritance of familial prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[248]  P. Correa.  Epidemiological correlations between diet and cancer frequency. , 1981, Cancer research.

[249]  C. Croce,et al.  Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.

[250]  S. Ripatti,et al.  Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. , 1998, Journal of the National Cancer Institute.